February 3, 2021
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing
January 20, 2021
Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United-States
JANUARY 19, 2021
Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19
JANUARY 19, 2021
Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States
January 7, 2021
Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021
December 16, 2020
Last patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia
December 14, 2020
Biophytis Presents SARA-OBS study results at the Annual Conference of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)
December 11, 2020
First Patient Enrolled in France in COVA, an International Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
December 3, 2020
Upcoming Potential Value Generating Milestones. Read the Press Release
December 1st, 2020
Biophytis is participating to: – The Geneva European Midcap digital event, December 1rst & 2 2020 – The “Anticovid” Biotech sector conference organized by the SFAF on Wednesday, December 9 – The 13th International SCWD virtual conference, December 11-13 2020